Serious adverse events (by day 28) · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in serious adverse events (by day 28) compared with saline placebo (low certainty).
1 finding from 1 review
Intervention not reported
Investigator‐defined adverse events · individuals with atrial fibrillation who are undergoing cardiac surgery
It is very uncertain whether the intervention changes investigator‐defined adverse events (very low certainty).
1 finding from 1 review
Adverse events (soft tissue trauma) · Individuals of any age with no reported disability that might affect toothbrushing (including people wearing orthodontic appliances)
1 finding from 1 review
Adverse events associated with transfusion · individuals with sickle cell disease who have had a stroke who have had long‐term red cell transfusions to prevent another stroke
1 finding from 1 review
Serious adverse events · patients with initial ART
TDF showed no clear difference in serious adverse events compared with AZT (high certainty).
1 finding from 1 review
Serious adverse events ‐ not reported · individuals with moderate to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events Descriptive information · patients with fibromyalgia
1 finding from 1 review
no estimate extracted
1996 participants
GRADE not reported
Adverse events: all grades · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in adverse events of any grade (by day 28) compared with saline placebo (low certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · hospitalised individuals with COVID‐19 (moderate to severe disease)
Bamlanivimab showed no clear difference in adverse events: grades 3 and 4 by day 30 compared with placebo (low certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · hospitalised individuals with COVID‐19 (moderate to severe disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: active lotion vs placebo · individuals at risk of pressure ulcer development
It is very uncertain whether active topical agent changes adverse events: active lotion vs placebo compared with placebo/control (very low certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… led to higher adverse events at grade 3 or 4 (by day 28) compared with saline placebo; GRADE not reported.
1 finding from 1 review
OR 4
3 participants
GRADE not reported
Adverse events associated with transfusion · individuals with sickle cell disease who are at risk of a primary stroke who have had long‐term red cell transfusions to prevent a stroke
1 finding from 1 review
Adverse events associated with transfusion · individuals with sickle cell disease who are at risk of a primary stroke who have had long‐term red cell transfusions to prevent a stroke
1 finding from 1 review
Adverse events associated with transfusion · individuals with sickle cell disease who are at risk of a primary stroke who have not had previous long‐term red cell transfusions
It is very uncertain whether long‐term red cell transfusion changes adverse events associated with transfusion compared with no transfusion (very low certainty).
1 finding from 1 review
Grades 3 and 4 adverse events ‐ not reported · individuals with moderate to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grades 3 and 4 adverse events · individuals with moderate or severe COVID‐19
Hyperimmune immunoglobulin from human plasma probably leads to higher adverse events at grades 3 to 4 up to 28 days compared with saline placebo (moderate certainty).
1 finding from 1 review
RR 4.09 [1.39, 12.01]
Studies not reported
Moderate
Intervention not reported
Adverse events associated with PET ‐ not reported · Individuals with Hodgkin lymphoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Any reported adverse events · participants with haemophilia
Prophylaxis regimen probably leads to higher any reported adverse events compared with on‐demand treatment (moderate certainty).
1 finding from 1 review